Stockscreener 앱 받기
3.72
0.53%
-0.02
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Kaplan Fox Announces an Investigation of Fulcrum Therapeutics, In - The National Law Review
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - Supply Chain Digital Magazine
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL) - GlobeNewswire Inc.
Kaplan Fox Reminds Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors of an Ongoing Securities Law Investigation - The National Law Review
Fulcrum Therapeutics faces investigation after stock halves due to halted sickle cell drug program. - Pluang
Fulcrum Therapeutics (FULC) Holds Steady at $3.77 as Traders Eye Range BoundariesBullish Pattern Stocks - siam.in
Fulcrum Therapeutics (FULC) Edges Higher to $3.79 as Shares Test Upper RangeMomentum Trade - siam.in
Kaplan Fox Urges Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Invest - The National Law Review
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Live Fulcrum Therapeutics, Inc. (FULC) Technical Analysis - Traders Union
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors of an Investigation Into Possible Securities Law Violations - NewMediaWire
Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Inv - The National Law Review
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: ... - pmg-ky3.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Investors to an Ongoing Investigation Into Possible Securities Law Violations - NewMediaWire
Kaplan Fox Alerts Fulcrum Therapeutics, Inc. (NASDAQ: FULC) Inves - The National Law Review
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Daily Tribune News
Kaplan Fox Investigates Fulcrum Therapeutics After Pociredir Discontinuation Triggers 51% Stock Collapse - kalkine.ca
Kaplan Fox Launches Investigation Into Fulcrum Therapeutics Following 51% Stock Plunge After Pociredir Program Halt - Kalkine Media
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Possible Securities Law Violations - The National Law Review
Greg Tourangeau, Former Fulcrum Therapeutics Officer, to Sell 14,062 Shares Worth $54,420 - Kalkine Media
Kaplan Fox Launches Securities Investigation Into Fulcrum Therapeutics After 51% Stock Collapse - kalkine.ca
Former Fulcrum Therapeutics (FULC) officer moves to sell about $54K in stock - Stock Titan
Fulcrum (NASDAQ: FULC) plans special cash dividend ahead of Slate Medicines merger - Stock Titan
Fulcrum Therapeutics faces securities probe aft... - Pluang
Fulcrum Therapeutics Inc. (FULC) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Kaplan Fox is Investigating Possible Securities Law Violations Against Fulcrum Therapeutics, Inc. (NASDAQ: FULC) - The Globe and Mail
Fulcrum Therapeutics Faces Securities Law Investigation After Pociredir Programme Discontinuation Triggers 51% Stock Drop - kalkine.ca
Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough? - Yahoo Finance
Fulcrum (FULC) Close: Ends Up by 0.26% at $3.84; Chart View: the Price Remains Bounded by the Supplied Support and Resistance in the Latest SessionVolatility Smile - vinanet.vn
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corpo - mykxlg.com
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the MergerHOWL, HZO, TYFG and FULC - Sahm
Fulcrum (FULC) Stock: Falls 0.52% to $3.83 at the Close; Chart View: Support at $3.64 and Resistance at $4.02 Frame the Range in the Latest SessionAnalyst Upgrade Stocks - vinanet.vn
Fulcrum (FULC) Quarter in Focus: The Available Earnings Metric Delivers a Beat in the Current Update; Market Response: Shares Finish 1.03% Higher on the DayEnergy Earnings Report - dars.gov.et
Fulcrum Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Fulcrum Therapeutics, Inc.FULC - Business Wire
Fulcrum Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Slate Medicines to Merge With Fulcrum Therapeutics - Cooley
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Contact the Firm Regarding an Investigation Into Possible Securities Law Violations - FinancialContent
Truist Financial Maintains Fulcrum Therapeutics(FULC.US) With Hold Rating - Moomoo
Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines - Sahm
Shareholder Alert: Ademi LLP investigates whether Fulcrum Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders - Sahm
Latham Advises Frazier Life Sciences on Private Placement Financing in Connection With Fulcrum Therapeutics and Slate Medicines Merger - Legal Desire
Latham Advises Frazier Life Sciences on Private Placement Financing With Fulcrum Slate Merger - Latham & Watkins LLP
Form 8K Fulcrum Therapeutics Inc For: 17 August By Investing.com - Investing.com South Africa
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement with Key Financial Details - Kalkine Media
Fulcrum Therapeutics (NASDAQ: FULC) backs $245M migraine venture with Slate - Stock Titan
Fulcrum Therapeutics to Merge With Slate Medicines in $245 Million Backed Migraine Play - finance.biggo.com
What's Going On With Fulcrum Therapeutics Stock Monday?Fulcrum Therapeutics (NASDAQ:FULC) - Benzinga
Slate Medicines goes public via Fulcrum merger to challenge PACAP migraine field - AllSci
Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies - Yahoo Finance
Fulcrum Therapeutics shuts down, reverse-merges with N.C. biotech Slate - The Business Journals
Kaplan Fox Investigates Fulcrum Therapeutics After Pociredir Discontinuation Triggers 51% Stock Plunge - kalkine.ca
Fulcrum Therapeutics Target of Unusually Large Options Trading (NASDAQ:FULC) - MarketBeat
Fulcrum Therapeutics and Slate Medicines to merge, refocusing combined company on migraine pipeline - The Pharma Letter
Fulcrum Therapeutics stock rises on Slate Medicines merger deal By Investing.com - Investing.com Australia
Fulcrum Therapeutics stock rises on Slate Medicines merger deal - Investing.com
Kaplan Fox Alerts Investors of Fulcrum Therapeutics, Inc. (NASDAQ: FULC) to Possible Securities Law Violations - The National Law Review
Fulcrum to merge with Slate in all-stock deal after drug setback - Reuters
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal - MarketBeat
0.85%
0.02%
자본화:
|
볼륨(24시간):